Published in:
01-04-2014 | Case Report
Successful treatment of AIDS-associated, primary CNS lymphoma with rituximab- and methotrexate-based chemotherapy and autologous stem cell transplantation
Authors:
T. Wolf, T. Kiderlen, J. Atta, C. Stephan, G. Kann, H.-R. Brodt, C. Brandts
Published in:
Infection
|
Issue 2/2014
Login to get access
Excerpt
Primary central nervous system lymphoma (PCNSL) is an Epstein–Barr virus (EBV)-associated, acquired immunodeficiency syndrome (AIDS)-defining malignancy. Even in the HAART (highly active antiretroviral therapy) era, in which the survival of patients with PCNSL has improved and the incidence has sharply reduced [
1,
2], the median survival time is <6 months [
1]. PCNSL has become a rare disease and, consequently, there is no consensus and only anecdotal evidence on the best treatment. Options include high-dose methotrexate (MTX) and radiotherapy. …